OncoGenex Pharma (OGXI) Presents Additional Data Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients
Tweet Send to a Friend
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from additional exploratory analyses of the Phase 3 SYNERGY trial demonstrating that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
